1. Yue X, Dhavale DD, Li J, Luo Z, Liu J, Yang H, Mach RH, Kotzbauer PT, Tu Z. (2018). Design, synthesis, and in vitro evaluation of quinolinyl analogues for α-synuclein aggregation. Bioorg Med Chem Lett. [Epub ahead of print].
  2. Barclay AM, Dhavale DD, Courtney JM, Kotzbauer PT, Rienstra CM. (2018). Resonance assignments of an α-synuclein fibril prepared in Tris buffer at moderate ionic strength. Biomol NMR Assign. [Epub ahead of print].
  3. Dhavale DD, Tsai C, Bagchi DP, Engel LA, Sarezky J, Kotzbauer PT. (2017). A sensitive assay reveals structural requirements for α-synuclein fibril growth. J Biol Chem. 292:9034-9050.
  4. Sundaram GS, Dhavale DD, Prior JL, Yan P, Cirrito J, Rath NP, Laforest R, Cairns NJ, Lee JM, Kotzbauer PT, Sharma V. (2016). Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer's Disease. Sci Rep. 6:35636.
  5. Chuang DY, Simonyi A, Kotzbauer PT, Gu Z, Sun GY. (2015). Cytosolic phospholipase A2 plays a crucial role in ROS/NO signaling during microglial activation through the lipoxygenase pathway. J Neuroinflammation. 12:199.
  6. Buddhala C, Loftin SK, Kuley BM, Cairns NJ, Campbell MC, Perlmutter JS, Kotzbauer PT. (2015). Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Ann Clin Transl Neurol. 2:949-959.
  7. Chu W, Zhou D, Gaba V, Liu J, Li S, Peng X, Xu J, Dhavale D, Bagchi DP, d'Avignon A, Shakerdge NB, Bacskai BJ, Tu Z, Kotzbauer PT, Mach RH. (2015). Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils. J Med Chem. 58:6002-6017.
  8. Sundaram GS, Dhavale D, Prior JL, Sivapackiam J, Laforest R, Kotzbauer P, Sharma V. (2015). Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer's disease. EJNMMI Res. 5:112.
  9. Campbell MC, Koller JM, Snyder AZ, Buddhala C, Kotzbauer PT, Perlmutter JS. (2015). CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology. 84:2413-2421.
  10. Zhang X, Jin H, Padakanti PK, Li J, Yang H, Fan J, Mach RH, Kotzbauer P, Tu Z. (2014). Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging α-Synuclein. Appl Sci (Basel). 4:66-78.
  11. Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT. (2015). Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease. Neurobiol Aging. 36:476-484.
  12. Armstrong RA, Kotzbauer PT, Perlmutter JS, Campbell MC, Hurth KM, Schmidt RE, Cairns NJ. (2014). A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease. J Neural Transm (Vienna). 121:171-181.
  13. Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI. (2013). Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 110:E3138-3147.
  14. Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, Kotzbauer PT. (2013). Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One. 8:E55031.
  15. Racette BA, Criswell SR, Lundin JI, Hobson A, Seixas N, Kotzbauer PT, Evanoff BA, Perlmutter JS, Zhang J, Sheppard L, Checkoway H. (2012). Increased risk of parkinsonism associated with welding exposure. Neurotoxicology. 33:1356-1361.
  16. Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS. (2012). Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol. 69:1326-1331.
  17. Yu L, Cui J, Padakanti PK, Engel L, Bagchi DP, Kotzbauer PT, Tu Z. (2012). Synthesis and in vitro evaluation of α-synuclein ligands. Bioorg Med Chem. 20:4625-4634.
  18. Engel LA, Jing Z, O'Brien DE, Sun M, Kotzbauer PT. (2010). Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism. PLoS One. 5:E12897.
  19. Li M, Husic N, Lin Y, Christensen H, Malik I, McIver S, LaPash Daniels CM, Harris DA, Kotzbauer PT, Goldberg MP, Snider BJ. (2010). Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. J Neurosci Methods. 189:56-64.
  20. Mancuso DJ, Kotzbauer P, Wozniak DF, Sims HF, Jenkins CM, Guan S, Han X, Yang K, Sun G, Malik I, Conyers S, Green KG, Schmidt RE, Gross RW. (2009). Genetic ablation of calcium-independent phospholipase A2{gamma} leads to alterations in hippocampal cardiolipin content and molecular species distribution, mitochondrial degeneration, autophagy, and cognitive dysfunction. J Biol Chem. 284:35632-35644.
  21. Gregory A, Westaway SK, Holm IE, Kotzbauer PT, Hogarth P, Sonek S, Coryell JC, Nguyen TM, Nardocci N, Zorzi G, Rodriguez D, Desguerre I, Bertini E, Simonati A, Levinson B, Dias C, Barbot C, Carrilho I, Santos M, Malik I, Gitschier J, Hayflick SJ. (2008). Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology. 71:1402-1409.
  22. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. (2008). Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci. 28:7687-7698.
  23. Malik I, Turk J, Mancuso DJ, Montier L, Wohltmann M, Wozniak DF, Schmidt RE, Gross RW, Kotzbauer PT. (2008). Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am J Pathol. 172:406-416.
  24. Kotzbauer PT, Holtzman DM. (2006). Expectations and challenges in the therapeutic use of neurotrophic factors. Ann Neurol. 59:444-447.
  25. Liang TW, Truax AC, Trojanowski JQ, Lee VM, Stern MB, Kotzbauer PT. (2006). Partial deficit of pantothenate kinase 2 catalytic activity in a case of tremor-predominant neurodegeneration with brain iron accumulation. Mov Disord. 21:718-722.
  26. Kotzbauer PT, Truax AC, Trojanowski JQ, Lee VM. (2005). Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci. 25:689-698.
  27. Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM. (2004). Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol. 187:279-288.
  28. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM. (2003). Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 300:636-640.